⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GANX News
Gain Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
GANX
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
globenewswire.com
GANX
Form 8-K
sec.gov
GANX
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
globenewswire.com
GANX
Form 8-K
sec.gov
GANX
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
globenewswire.com
GANX
Form 8-K
sec.gov
GANX
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
globenewswire.com
GANX
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
globenewswire.com
GANX
Form 8-K
sec.gov
GANX